MedTrace Logo

To Demonstrate the Relative Bioequivalency of Generic Haloperidol Tablets Versus Haldol in Normal Volunteers

NCT00946491 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-03-28

No results posted yet for this study

Summary

To demonstrate the relative bioequivalency of generic Haloperidol tablets versus Haldol in normal volunteers.

Conditions

Interventions

DRUG

Haloperidol 10 mg Tablets (Cord Laboratories)

DRUG

Haldol 10 mg Tablets (McNeil Pharmaceuticals)

Sponsors & Collaborators

Principal Investigators

  • Philip T. Leese, M.D. · Quincy Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
35 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1987-04-30
Primary Completion
1987-05-31
Completion
1987-05-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00946491 on ClinicalTrials.gov